Results from AGATE II, the first Phase 3 trial to evaluate ombitasvir/paritaprevir/ritonavir with ribavirin for patients with chronic hepatitis C virus (HCV) genotype 4 (GT4) infection in Egypt, found the regimen to be “generally well tolerated,” according to a presentation at The Liver Meeting® 2015.
Patients from the advanced cirrhosis cohort of the Phase 3 ALLY-1 study had high rates of sustained virologic response (SVR12) when treated with daclatasvir/sofosbuvir/ribavirin, as well as improved clinical and biochemical indicators of liver disease, investigators reported at The Liver Meeting® 2015.
Among patients with treatment-naïve genotype 1a (GT1a) hepatitis C virus (HCV) infection treated with grazoprevir/elbasvir with or without ribavirin, baseline HCV RNA level and baseline NS5A resistance-associated variants (RAVs) conferring a greater than 5-fold shift in potency of elbasvir in vitro were identified as significant predictors of sustained virologic response 12 weeks after end of therapy (SVR12), a study concluded at The Liver Meeting® 2015.
Cirrhotic patients who develop hepatocellular carcinoma (HCC) despite secondary prevention therapy with nucleos(t)ide analog (NUC) treatment appear to have poor recurrence-free survival (RFS) after surgery than those who do not undergo secondary prevention, reported authors of a new study presented at The Liver Meeting® 2015.
Non-adherence to antiviral regimens may be predicted by the use of pegylated interferon, ribavirin, duration of treatment, and lower baseline and on-treatment patient-reported outcomes (PRO) scores, reported Zobair Younossi, MD, MPH, from Inova Fairfax Hospital, Falls Church, VA, at The Liver Meeting® 2015.
Nucleos(t)ide analog (NA) treatment reduces the risk of hepatocellular carcinoma (HCC) recurrence and possibly death in patients with chronic hepatitis B virus (HBV) infection, particularly among those who received tumor resection and local ablative treatment for HCC, according to research presented at The Liver Meeting® 2015.
Use of aspirin significantly reduced the risk of three subtypes of cholangiocarcinoma, data presented at The Liver Meeting® 2015 have shown.
Treatment with non-selective beta-blockers in cirrhotic patients with refractory ascites may further deteriorate cardiac function, researchers reported at The Liver Meeting® 2015.
Please login or register first to view this content.
